Immune cell therapy takes on tough autoimmune diseases

NCT ID NCT06822881

Recruiting now Disease control Sponsor: Beijing GoBroad Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a new treatment called CT1190B CAR-T cell therapy for people with moderate to severe lupus or scleroderma that hasn't responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and potentially calm the overactive immune system. The study will enroll 27 participants to check safety and look for early signs of effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CT1190B CAR-T cells (a type of immune cell therapy)
What this could lead to: If successful, this could point toward a new treatment option for people with hard-to-control lupus or scleroderma.
What could go wrong: This is a very early Phase 1 trial with only 27 people, so safety and effectiveness are not yet proven. CAR-T therapy can cause serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systemic lupus erythematosus systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) SYSTEMIC SCLEROSIS (SSC)

Contacts and locations

Locations

Beijing GoBroad Hospital
RECRUITING

Beijing, Beijing Municipality, 102200, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.